



**Universiteit
Leiden**
The Netherlands

Gender differences in antithrombotic treatment in patients with atrial fibrillation from Spain versus the rest of Western Europe: GLORIA-AF Program

Lopez-Sendon, J.L.; Alonso-Rodriguez, D.; Baron-Esquivias, G.; Cosin-Sales, J.; Marin, F.; Galera-Llorca, J.; ... ; Spanish GLORIA-AF Investigators

Citation

Lopez-Sendon, J. L., Alonso-Rodriguez, D., Baron-Esquivias, G., Cosin-Sales, J., Marin, F., Galera-Llorca, J., ... Lip, G. Y. H. (2022). Gender differences in antithrombotic treatment in patients with atrial fibrillation from Spain versus the rest of Western Europe: GLORIA-AF Program. *Medicina Clínica*, 159(4), 177-182. doi:10.1016/j.medcli.2021.09.016

Version: Publisher's Version

License: [Creative Commons CC BY-NC-ND 4.0 license](https://creativecommons.org/licenses/by-nc-nd/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3566950>

Note: To cite this publication please use the final published version (if applicable).



Original article

Gender differences in antithrombotic treatment in patients with atrial fibrillation from Spain versus the rest of Western Europe. GLORIA-AF Program



José L. López-Sendón^{a,*}, David Alonso-Rodríguez^b, Gonzalo Barón-Esquivias^c, Juan Cosin-Sales^d, Francisco Marín^e, Jordi Galera-Llorca^f, Natalia Jiménez^g, Sabrina Marler^h, Menno V. Huisman^{i,1}, Gregory Y.H. Lip^{j,1}, on behalf of the Spanish GLORIA-AF investigators

^a Hospital Universitario La Paz, IDIPAZ, CIBER-CV, Paseo de la Castellana 261, 28046 Madrid, Spain

^b Complejo Asistencial Universitario, C/Altos de Nava s/n, León, Spain

^c Clínica ABP Salud, Sevilla, Av. Manuel Siurot, 19 bajo, 41013, Sevilla, Spain

^d Hospital Arnau de Vilanova, Carrer de Sant Clement, 12, 46015 Valencia, Spain

^e Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, CIBERCV, Ctra. Madrid-Cartagena, s/n, Murcia, Spain

^f TFS Health Science, Passeig de Gracia 11, 08007 Barcelona, Spain

^g Boehringer Ingelheim Spain, Carrer de Prat de la Riba, 50, 08174 Sant Cugat del Vallès, Barcelona, Spain

^h Boehringer Ingelheim Pharmaceuticals Inc, 900 Ridgebury Rd, Ridgefield, CT 06877, USA

ⁱ Leiden University Medical Centre, Leiden, Albinusdreef 2, 2333 ZA Leiden, Netherlands

^j University of Liverpool and Liverpool Heart & Chest, Thomas Dr, Liverpool L14 3PE, UK

ARTICLE INFO

Article history:

Received 28 June 2021

Accepted 27 September 2021

Available online 8 December 2021

Keywords:

Atrial fibrillation

Gender

GLORIA-AF

Direct oral anticoagulants

Antivitamin K antagonists

ABSTRACT

Background and objective: Thromboembolic risk is higher in women than men with non-valvular atrial fibrillation (NVAF). Published data indicate variability in antithrombotic use by gender and region. We analyzed gender-specific antithrombotic treatment patterns in Spain and rest of Western Europe (rWE) in patients with NVAF.

Methods: GLORIA-AF (Phase III) is a global, prospective, observational study which enrolled newly diagnosed NVAF patients with $CHA_2DS_2-VASc \geq 1$ (2014–2016). Analyses were performed comparing antithrombotic treatments by gender in Spain and rWE.

Results: This analysis included 1163 and 7972 patients from Spain and rWE, respectively. Stroke risk was higher in women than men in both Spain and rWE. While in rWE, bleeding risk and antithrombotic treatment pattern were similar between genders, in Spain bleeding risk in women was lower and more females compared to men received OACs (95.0% versus 92.4%, $d = -0.1078$, respectively). Fewer Spanish patients received direct oral anticoagulants (DOACs) (women 32.1%, men 25.3%) than vitamin-K-antagonists (VKAs) (women 63.0%, men 67.1%) vs. rWE patients. In Spain women received more DOACs compared to men (56.0% versus 44.0%).

Conclusions: OAC rates were higher in Spain as compared to rWE. More women received OACs in Spain, while in rWE no difference by gender was observed. DOACs in rWE are the most prescribed OAC while in Spain, due to prescription barriers, its use remains low for both genders and VKAs are preferred. Spanish women received more DOACs compared to men. (NCT01468701).

© 2021 The Authors. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

* Corresponding author.

E-mail address: jlopezsendon@gmail.com (J.L. López-Sendón).

¹ Drs Huisman and Lip are co-chairs of the GLORIA-AF Registry and joint senior authors.

Diferencias de sexo en el tratamiento antitrombótico en pacientes con fibrilación auricular en España y el resto de Europa Occidental. Registro GLORIA-AF

R E S U M E N

Palabras clave:
Fibrilación auricular
Sexo
GLORIA-AF
Anticoagulantes directos
Antagonistas de la vitamina K

Antecedentes y objetivo: El riesgo tromboembólico es mayor en mujeres que en varones con fibrilación auricular no valvular (FANV). Existen diferencias en el uso de anticoagulantes (ACO) según sexo y zona geográfica. Se estudiaron los patrones de anticoagulación por sexo en España y el resto de Europa Occidental (rEO) en pacientes con FANV.

Métodos: GLORIA-AF es un estudio observacional prospectivo (fase III) que incluyó a pacientes con diagnóstico reciente de FANV y $\text{CHA}_2\text{DS}_2\text{-VASc} > 1$ (2014–2016). Se analizó la prescripción de anticoagulantes por sexo en España y el rEO.

Resultados: Se incluyó a 1.163 pacientes de España y 7.972 del rEO. El riesgo de ictus fue superior en mujeres tanto en España como en el rEO. El riesgo de hemorragia y el tratamiento antitrombótico fueron similares en ambos sexos en el rEO; en España, el riesgo de hemorragia fue menor en mujeres y estas recibieron más ACO que los varones (95,0% vs. 92,4%, $d = -0,1078$). En España, menos pacientes recibieron ACO directos (ACOD) (mujeres 32,1%, varones 25,3%) vs. antagonistas de la vitamina K (AVK) (mujeres 63,0%, varones 67,1%), y las mujeres recibieron más ACOD que los varones (56,0% vs. 44,0%).

Conclusiones: En España se emplearon más ACO que en el rEO y más mujeres fueron tratadas con ACO, mientras que en el rEO no hubo diferencias por sexo. En el rEO, los ACOD se emplearon más. En España, los ACOD se emplean menos por restricciones de prescripción y se emplean más los AVK. Las mujeres españolas reciben más ACOD que los varones. (NCT01468701).

© 2021 Los Autores. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Recommendations for long-term oral anticoagulation in patients with atrial fibrillation (AF) are well established in major clinical guidelines and consensus.^{1–4} Direct oral anticoagulants (DOACs) are preferred over vitamin K antagonists (VKAs) for prevention of stroke due to a better efficacy and safety profile.^{1,5,6} In 2016, DOACs were used in less than 20% of Spanish patients with non-valvular atrial fibrillation (NVAf).⁷ In addition, at present there are some local regulatory recommendations in Spain where oral anticoagulants (OACs) are positioned on the basis of a rational use in its National Health System (SNS).⁸ Thus, DOACs are prescribed in Spain as second line after VKAs while these agents are considered first line therapy in rWE countries.

Furthermore, although studies suggest that women with NVAf are at increased risk of stroke than men,^{9–11} published data indicate variability in anticoagulation by gender.^{12–17} The Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), is a large, three-phased, global prospective registry on patients with newly diagnosed NVAf. This sub-analysis within Phase III of GLORIA-AF explored whether there were any gender differences in the prescription of antithrombotic therapies and to explore the overall differences in antithrombotic treatment patterns among NVAf patients from Spain and the rest of Western Europe (rWE).

The objectives of the present analysis include: (i) To explore the use of different antithrombotic strategies across gender in Spanish versus rWE, (ii) to determine the possible factors related to the use of OACs versus non-use of OACs in the Spanish population, and (iii) to analyze gender differences in the use of DOACs in Spain vs the rWE.

Methods

Study design

The design of the GLORIA-AF registry program has been published.¹⁸ Briefly GLORIA-AF is a prospective, three-phase, global registry program, which assessed the patient characteristics

influencing the choice of antithrombotic agent and its outcomes in NVAf patients with ≥ 1 stroke risk factors.¹⁸

Adult patients with newly diagnosed NVAf (<3 months from arrhythmia onset) and a $\text{CHA}_2\text{DS}_2\text{-VASc}$ score¹⁹ of >1 were consecutively enrolled. Globally, subjects were recruited at 935 clinical sites in 38 countries reflecting a wide variety of health care settings (general practices, specialist offices, community hospitals, university hospitals, outpatient care centers, anticoagulation and clinics).

Demographic and baseline characteristics, including stroke and bleeding risk scores ($\text{CHA}_2\text{DS}_2\text{-VASc}$ and HAS-BLED²⁰) and concomitant medications were collected for all eligible patients by prescribed antithrombotic treatment at the baseline visit.

Patients from Spain consecutively enrolled at 29 clinical sites were compared with patients from rWE enrolled at 305 clinical sites from the following 13 countries: Austria, Belgium, Denmark, France, Germany, Greece, Ireland, Italy, The Netherlands, Norway, Portugal, Switzerland and the United Kingdom.

Data collection and timelines

The enrolment of Phase III GLORIA-AF was conducted from January 2014 to December 2016. All clinical data were collected and processed using a web-based Electronic Data Capture System (Florida, USA) over a secure network and a complete electronic audit trail. Quality of data entered into the electronic database was monitored and audited during the course of the program.

Statistical analysis

Baseline data were summarized descriptively. Continuous variables were reported as mean and standard deviation (SD). Categorical variables were reported as absolute frequencies and percentages. To compare baseline characteristics, antithrombotic therapy and OACs use by gender within Spain and rWE, standardized differences (d) were used. The standardized difference with absolute value <0.1 was considered as balance between groups.

Table 1
Baseline characteristics and comorbidities for all eligible patients in Spain and rest of Western Europe (rWE).

Baseline characteristics	Spain			Rest of Western Europe		
	Female (n = 583)	Male (n = 580)	d	Female (n = 3503)	Male (n = 4469)	d
Age, mean ± SD, years	75.3 ± 9.1	71.7 ± 10.5	−0.3585	74.0 ± 9.7	70.9 ± 10.0	−0.3114
CHA ₂ DS ₂ -VASC, mean ± SD	4.0 ± 1.3	3.0 ± 1.5	−0.7379	3.8 ± 1.5	2.8 ± 1.4	−0.6974
CHA ₂ DS ₂ -VASC score = 1, n (%)	10 (1.7)	101 (17.4)	0.5539	135 (3.9)	862 (19.3)	0.4972
HAS-BLED score, mean ± SD ^a	1.2 ± 0.7	1.3 ± 0.9	0.1400	1.3 ± 0.8	1.4 ± 0.9	0.0806
CrCl, mean ± SD, mL/min ^b	71.4 ± 31.1	83.0 ± 35.8	0.3465	71.6 ± 30.9	85.5 ± 39.7	0.3915
Symptomatic AF, n (%)	205 (35.2)	151 (26.0)	−0.1991	1230 (35.1)	1223 (27.4)	−0.1677
Paroxysmal AF, n (%)	251 (43.1)	206 (35.5)	−0.1548	1897 (54.2)	2067 (46.3)	−0.1585
Persistent AF, n (%)	217 (37.2)	251 (43.3)	0.1237	1240 (35.4)	1913 (42.8)	0.1522
Previous stroke, n (%)	35 (6.0)	57 (9.8)	0.1420	470 (13.4)	598 (13.4)	−0.0011
Myocardial infarction, n (%)	29 (5.0)	81 (14.0)	0.3108	221 (6.3)	632 (14.1)	0.2607
Coronary artery disease, n (%)	40 (6.9)	99 (17.1)	0.3185	340 (9.7)	945 (21.1)	0.3208
Congestive heart failure, n (%)	134 (23.0)	170 (29.3)	0.1443	483 (13.8)	919 (20.6)	0.1804
Hypertension history, n (%)	461 (79.1)	417 (71.9)	−0.1674	2518 (71.9)	3211 (71.9)	−0.0007
Diabetes mellitus, n (%)	140 (24.0)	166 (28.6)	0.1048	618 (17.6)	961 (21.5)	0.0974
Antiplatelet use, n (%)	67 (11.5)	102 (17.6)	0.1735	505 (14.4)	887 (19.8)	0.1445

AF, atrial fibrillation; CrCl, creatinine clearance; d, standardized difference (male patients minus female patients); SD, standard deviation.

^a HAS-BLED: data missing for 29 (5.0%) Spanish female patients, 47 (8.1%) Spanish male patients, 390 (11.1%) rWE female patients, and 600 (13.4%) rWE male patients.

^b CrCl: data missing for 83 (14.2%) Spanish female patients, 76 (13.1%) Spanish male patients, 545 (15.6%) rWE female patients, and 759 (17.0%) rWE male patients.

Results

Baseline characteristics

The analysis included a total of 9135 eligible patients, 1163 and 7972 from Spain and rWE, respectively (Table 1). In Spain, 583 (50.1%) of patients were female vs 3503 (43.9%) in rWE. Women were older in both Spain and rWE compared to men. The mean (±SD) age was 75.3 ± 9.1 (Spanish females) vs. 71.7 ± 10.5 (Spanish males) ($d = -0.3585$) and 74.0 ± 9.7 (rWE females) vs. 70.9 ± 10.0 (rWE males) ($d = -0.3114$).

Based on the CHA₂DS₂-VASC score, stroke risk was higher in Spanish females vs males (4.0 ± 1.3 and 3.0 ± 1.5; $d = -0.7379$) and also in rWE females vs males (3.8 ± 1.5 and 2.8 ± 1.4; $d = -0.6974$). Bleeding risk was lower in Spanish females vs males (1.2 ± 0.7 and 1.3 ± 0.9 respectively, $d = 0.1400$); a similar trend was observed among rWE patients (1.3 ± 0.8 and 1.4 ± 0.9 respectively), as assessed by the HAS-BLED score. Bleeding risk was unknown for 5.0% of Spanish women and for 8.1% for men, and for 11.1% of rWE women and for 13.4% for men. In Spain, mean creatinine clearance was lower in women than in men (71.4 ± 31.1 mL/min vs 83.0 ± 35.8 mL/min; $p = 0.3465$) and the same occurred in the rWE (71.6 ± 30.9 mL/min vs 85.5 ± 39.7 mL/min; $p = 0.3915$). In the rWE group, prevalence of previous stroke, hypertension history and diabetes, were balanced between genders. A higher proportion of men, more than double, had coronary artery disease and prior myocardial infarction compared to women in both Spanish and rWE populations. Among the Spanish population females had a higher proportion of hypertension, however males had a higher proportion of previous stroke, congestive heart failure and diabetes mellitus. Among rWE patients, males had a higher proportion for congestive heart failure, myocardial infarction, and coronary artery disease as compared to females.

Use of different antithrombotic strategies

Antithrombotic treatment patterns by gender are presented in Fig. 1. Overall, the prevalence of OACs (DOACs and VKAs) in Spain and rWE was high, since 93.7% and 89.0% of the patients, respectively, were prescribed OACs.

When analyzing gender differences in OAC use, Spanish women showed slightly higher figures than men (females 95.0%, males 92.4%; $d = -0.1078$). On the contrary, OACs use in rWE was balanced between genders (88.6% vs 89.3%, respectively; $d = 0.0247$).

However, 7.6% of males in Spain did not receive OACs (no treatment or antiplatelets alone) while it was only 4.8% in females. This gender difference was not observed in rWE since 11.4% females did not receive OACs vs 10.7% in males.

Spanish patients were prescribed fewer DOACs (women 32.1%, men 25.3%) than VKAs (women 63.0%, men 67.1%) vs. rWE patients. Subjects in rWE received more DOACs (69.3%, both genders) than VKAs (women 19.2%, men 20.0%).

Gender and use of OACs

According to our study, a total of 8184 patients received OACs in WE (Spain and rWE combined). Of these, 5859 (71.6%) received DOACs and 2325 (28.4%) received VKAs. When analyzing gender differences by geographical region it was observed that 334 patients in Spain received DOACs. Of these, 56.0% were female and 44.0% were male. Of the 5525 patients receiving DOACs in rWE, 44.0% were female and 56.0% were male.

As for patients receiving VKAs, 756 did so in Spain and 1569 in rWE. The percentage of Spanish patients by gender is similar (48.5% women and 51.5% men). In contrast, fewer women (42.9%) received VKAs than men (57.1%) at rWE.

Discussion

General introduction

Our study shows high use of OAC in Spain as compared with the rWE, in particular women treated with OACs and DOAC in a higher proportion than men in Spain. However, DOACs are used only in a fraction of patients as compared with the rWE countries.

Use of different antithrombotic strategies

Observational and large registries, as the GLORIA-AF,²¹ are essential to characterize treatment patterns and responses in clinical practice. These data provide long-term safety and effectiveness information in heterogeneous populations and raise the level of evidence upon which to base treatment recommendations.

The global results of the total population included in the GLORIA registry concluded that the prevalence of anticoagulant use is similar in both genders.²² However, the conclusions of our work differ from this one. In Spain, we have a different scenario since DOACs are prescribed less than VKAs, unlike in the rWE. While the




Fig. 1. Antithrombotic treatment patterns by gender in Spain versus rest of Western Europe (rWE). DOAC, direct oral anticoagulant (include DOACs +/- antiplatelets); VKA, vitamin K antagonist (includes VKA +/- antiplatelets); rWE: rest of Western Europe.

first DOAC in this country was marketed in 2008, it was shown in 2015 a percentage of use of DOACs of 15.8% compared to 63.6% of VKAs.²³ Prescription for DOACs in Spain were significantly lower as compared to DOAC prescription in neighboring countries such as France, Italy, Portugal, or Germany (38.7%, 35.1%, 50% and 53.0% respectively). Other authors, early 2016, published that DOACs were used in fewer than 20% of Spanish patients with NVAF due to their impact on the health budget.⁷

Factors related to the use of OACs in Spain

At present, the prescription of DOACs reimbursed by the Spanish Health system requires an inspection visa to ensure its rational use according to the clinical conditions defined in the current version of the DOACs' Therapeutic Positioning Report (IPT), published by the Spanish Medicines Agency late in 2016.²⁴ These recommendations differ from those of the ESC (2016), limiting the use of DOACs to second-line treatment in most cases. Hence, VKA remains the recommended treatment option for the majority of patients. DOACs can only be considered as a therapeutic option in the NVAF population if they satisfy following criteria: (1) known hypersensitivity/contraindication to acenocoumarol or warfarin, (2) history of intracranial hemorrhage (ICH), previous ischemic stroke who have clinical and neuroimaging criteria of high ICH risk and (3) patients with VKA who suffer severe arterial thromboembolic events despite good international normalized ratio (INR) control.⁸ All of this implies that new patients with NVAF requiring anticoagulation and those on VKAs with good INR control are not DOAC candidates.

Gender and use of OACs

Women with NVAF are at increased risk of stroke than men,^{9–11} and neglecting female sex as a risk modifier may underestimate stroke risks in NVAF patients age >65 or with ≥1 additional stroke risk factors.²⁵ As expected, both in Spain and in rWE, a difference in the CHA₂DS₂-VASc score between men and women of 1 point was observed, considering female sex as a risk factor for

stroke in patients with AF within the same scale. Current European guidelines state that women with CHA₂DS₂-VASc = 1 (1 point for female gender only) are at “truly low-risk” for stroke and should not be anticoagulated because this brings no benefit but may cause harm.^{26–28} By contrast, anticoagulation should be considered in patients with 1 non-gender-related risk factors for stroke, that is, CHA₂DS₂-VASc = 1 for men and CHA₂DS₂-VASc = 2 for women.²⁹

We observed in the current analysis that women with NVAF have a higher risk of stroke than men and this is reflected in the OAC prescription pattern, i.e., a higher proportion of female patients received OACs as compared to their male counterparts in Spain.

Although the percentage of DOACs use of 28.7% in Spain shown by the current analysis is slightly higher than other previously published data, it continues to be inadequate. These figures are lower than the ones observed in neighboring countries and also lower than expected, given current guidelines and given the number of patients uncontrolled while taking VKAs. Therefore, all those barriers that make access to DOACs difficult should be addressed to improve the outcomes in patients requiring anticoagulation. Greater attention to gender-specific risks and treatment patterns will improve the effectiveness of stroke prevention in women and ultimately reduce stroke-related severe outcomes.

Limitations

GLORIA-AF included patients only from participating sites and most patients came from Cardiology practices. There are limitations in generalizing the finding of this data and the results may not be representative of the overall AF population; however, as a representative of other registries which included newly diagnosed AF population. Also, male patients with a low risk of stroke (CHA₂DS₂-VASc score = 0) were not recruited (per protocol) so no data on this subpopulation is available. The current analysis is only based on the prescription pattern at time of AF diagnosis (baseline); therefore, no conclusions can be drawn on the quality of anticoagulation or potential changes of OAC use over time. Only new-onset AF patients were enrolled preventing extrapolating findings to patients with >3 months from arrhythmia onset. Despite the patients recruited

in the registry are high, only 1163 Spanish patients (583 women) were analyzed so numbers can be somewhat limited to extrapolate the information to the entire population. Subjects and investigators knew they joined a registry program so this might have led to higher overall compliance/anticoagulation rates compared with the general population. It needs to be considered that WE countries may have some degree of varying healthcare systems, reimbursement policies and enrolling sites. In this sense, a bias arising from direct comparison of antithrombotic treatment pattern between rWE and Spain cannot be ruled out. It also should be noted that the current DOAC prescription rates, both in Spain and in the rWE, are higher than the ones reported in the GLORIA registry 5 years ago.

Conclusions

In rWE DOACs have been established as the preferred OAC treatment, while in Spain due to prescription barriers, DOAC use remains low for both genders. In Spain for both genders, fewer patients were prescribed DOACs than VKAs. While in the rWE population there appears no difference in OAC use by gender. In Spain, a higher percentage of women appears to be treated with OAC particularly taking into consideration the higher stroke risk in women.

Ethical considerations

The procedures used in the patients have been carried out in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki), with the authorization of the Clinical Research Ethics Committees of the institutions of origin of the patients.

Funding

The GLORIA-AF Registry Program was funded by Boehringer Ingelheim. ClinicalTrials.gov Identifier: NCT01428765.

Conflict of interest

Jose L. Lopez Sendon report research grants from Bayer, Merck, Pfizer-BMS, Sanofi, Boehringer-Ingelheim and personal fees from Menarini and Daiichi Sankyo.

David Alonso has been a speaker for Bayer, BMS/Pfizer, Boehringer Ingelheim, and Daiichi-Sankyo.

Gonzalo Barón-Esquivias. Francisco Marín report consultant fees from Boehringer Ingelheim and speaker fees from Bayer, BMS/Pfizer, Boehringer Ingelheim, Astra-Zeneca and Daiichi-Sankyo.

Juan Cosin-Sales has been a consultant and speaker for Bayer, BMS/Pfizer, Boehringer Ingelheim and Daiichi-Sankyo.

Natalia Jiménez and Sabrina Marler are employees of Boehringer Ingelheim.

Professor Huisman reports grants from ZonMW Dutch Healthcare Fund, grants, and personal fees from Boehringer-Ingelheim, Pfizer-BMS, Bayer Health Care, Aspen, Daiichi-Sankyo, outside the submitted work.

Professor Lip has been a consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseeon, and Daiichi-Sankyo. He has been a speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees directly received personally.

Acknowledgements

The authors would like to acknowledge María Romero who provided medical writing support on behalf of Springer Healthcare.

References

- Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J*. 2021;42:373–498.
- Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of Non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. *Eur Heart J*. 2018;39:1330–93. <http://dx.doi.org/10.1093/eurheartj/ehy136>.
- Calkins H, Lin, Chen Y, Cigarroa JE, Cleveland JC, Ellinor PT, et al. ACC/HRS guideline for the management of patients with atrial fibrillation circulation. *Circulation*. 2019;140:125–51. <http://dx.doi.org/10.1161/CIR.0000000000000665>.
- Lip GYH, Banerjee A, Boriani G, En Chiang C, Fargó R, Freedman B, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. *Chest*. 2018;154:1121–201. <http://dx.doi.org/10.1016/j.chest.2018.07.040>.
- Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet*. 2014;383:955–62. [http://dx.doi.org/10.1016/S0140-6736\(13\)62343-0](http://dx.doi.org/10.1016/S0140-6736(13)62343-0).
- Freedman B, Potpara TS, Lip GYH. Stroke prevention in atrial fibrillation. *Lancet*. 2016;388:806–17. [http://dx.doi.org/10.1016/S0140-6736\(16\)31257-0](http://dx.doi.org/10.1016/S0140-6736(16)31257-0).
- Segú J. Acceso a los anticoagulantes de acción directa en España. *Rev Espan Cardiol Supl*. 2016;16:55–9. [http://dx.doi.org/10.1016/S1131-3587\(16\)30016-4](http://dx.doi.org/10.1016/S1131-3587(16)30016-4).
- Medicamento AEdel. Criterios y recomendaciones generales para el uso de nuevos anticoagulantes orales (NACO) en la prevención del ictus y la embolia sistémica en pacientes con fibrilación auricular no valvular. Ministerio de Sanidad, Servicios sociales e Igualdad; 2013. p. 1–11.
- Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I–III clinical trials. *Stroke*. 1999;30:1223–9. <http://dx.doi.org/10.1161/01.STR.30.6.1223>.
- Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG, et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the Anticoagulation and Risk factors in Atrial fibrillation (ATRIA) study. *Circulation*. 2005;112:1687–91. <http://dx.doi.org/10.1161/CIRCULATIONAHA.105.553438>.
- Mikkelsen AP, Lindhardsen J, Lip GYH, Gislason GH, Torp-Pedersen C, Olesen JB. Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study. *J Thromb Haemost*. 2012;10:1745–51. <http://dx.doi.org/10.1111/j.1538-7836.2012.04853.x>.
- Cheng EY, Kong MH. Gender differences of thromboembolic events in atrial fibrillation. *Am J Cardiol*. 2016;117:1021–7. <http://dx.doi.org/10.1016/j.amjcard.2015.12.040>.
- Humphries KH, Kerr CR, Connolly SJ, Klein G, Boone JA, Green M, et al. New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. *Circulation*. 2001;103:2365–70. <http://dx.doi.org/10.1161/01.CIR.103.19.2365>.
- Avgil Tsadok M, Jackevicius CA, Rahme E, Humphries KH, Behloul H, Pilote L. Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. *JAMA*. 2012;307:1952–8. <http://dx.doi.org/10.1001/jama.2012.3490>.
- Dagres N, Nieuwlaet R, Vardas PE, Andresen D, Lévy S, Cobbe S, et al. Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe. A report from the Euro Heart Survey on atrial fibrillation. *J Am Coll Cardiol*. 2007;49:572–7. <http://dx.doi.org/10.1016/j.jacc.2006.10.047>.
- Lip GYH, Laroche C, Boriani G, Cimaglia P, Dan GA, Santini M, et al. Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. *Europace*. 2014;17:24–31. <http://dx.doi.org/10.1093/europace/euu155>.
- Dentali F, Sironi AP, Gianni M, Orlandini F, Guasti L, Grandi AM, et al. Gender difference in efficacy and safety of nonvitamin K antagonist oral anticoagulants in patients with nonvalvular atrial fibrillation or venous thromboembolism: a systematic review and a meta-analysis of the literature. *Seminars in thrombosis and hemostasis*, vol. 41. Thieme Medical Publishers Inc.; 2015. p. 774–87. <http://dx.doi.org/10.1055/s-0035-1564042>.
- Huisman MV, Lip GYH, Diener HC, Dubner SJ, Halperin JL, Ma CS, et al. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. *Am Heart J*. 2014;167:329–34. <http://dx.doi.org/10.1016/j.ahj.2013.12.006>.
- Lip GYH, Nieuwlaet R, Pisters R, Lane DA, Crijns HJGM, Andresen D, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. *Chest*. 2010;137:263–72. <http://dx.doi.org/10.1378/chest.09-1584>.
- Pisters R, Lane DA, Nieuwlaet R, De Vos CB, Crijns HJGM, Lip GYH, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart survey. *Chest*. 2010;138:1093–100. <http://dx.doi.org/10.1378/chest.10-0134>.
- Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Graham R, Mancher M, Wolman DM, Greenfield S, Steinberg E. Clinical practice guidelines we can trust. National Academies Press; 2011. <http://dx.doi.org/10.17226/13058>.

22. Mazurek M, Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener H-C, et al. Gender differences in antithrombotic treatment for newly diagnosed atrial fibrillation: the GLORIA-AF Registry Program. *Am J Med.* 2018;131:945–55, e3.
23. Barón-Esquivias G, Gómez S, Brufau H, García L, Amo C, Gutiérrez JM, et al. Care indicators in patients with atrial fibrillation: assessment of sex differences and management of clinical problems. *Rev Españ Cardiol (English Ed).* 2016;69:384–91, <http://dx.doi.org/10.1016/j.rec.2015.08.021>.
24. del Medicamento AE. Criterios y recomendaciones generales para el uso de nuevos anticoagulantes orales (NACO) en la prevención del ictus y la embolia sistémica en pacientes con fibrilación auricular no valvular. *Agenc Españ Med.* 2016:1–11.
25. Nielsen PB, Overvad TF. Female sex as a risk modifier for stroke risk in atrial fibrillation: using CHA2DS2-VASc versus CHA2DS2-VA for stroke risk stratification in atrial fibrillation: a note of caution. *Thromb Haemost.* 2020;120:894–8, <http://dx.doi.org/10.1055/s-0040-1710014>.
26. Haim M, Hoshen M, Reges O, Rabi Y, Balicer R, Leibowitz M. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. *J Am Heart Assoc.* 2015;4:e001486, <http://dx.doi.org/10.1161/JAHA.114.001486>.
27. McManus DD, Rienstra M, Benjamin EJ. An update on the prognosis of patients with atrial fibrillation. *Circulation.* 2012;126:e143, <http://dx.doi.org/10.1161/CIRCULATIONAHA.112.129759>.
28. Ball J, Carrington MJ, McMurray JJV, Stewart S. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. *Int J Cardiol.* 2013;167:1807–24, <http://dx.doi.org/10.1016/j.ijcard.2012.12.093>.
29. Lip GYH, Freedman B, de Caterina R, Potpara TS. Stroke prevention in atrial fibrillation: past, present and future comparing the guidelines and practical decision-making. *Thromb Haemost.* 2017;117:1230–9, <http://dx.doi.org/10.1160/TH16-11-0876>.